Showing results (11-20 of 67) with videos related to
Sort By:
Pageof 7
Annals of the New York Academy of Sciences|December 13, 1996
Camptothecin and its analogs. An overview of their potential in cancer therapeuticsF M Muggia, I Dimery, S G ArbuckBiochimica Et Biophysica Acta|September 28, 1998
Clinical applications of the camptothecinsC H Takimoto, J Wright, S G ArbuckGynecologic Oncology|December 1, 1994
Options for primary chemotherapy of epithelial ovarian cancer: taxanesE L Trimble, S G Arbuck, W P McGuireCancer Chemotherapy and Pharmacology|September 28, 1998
National Cancer Institute Clinical Trials Program in Colorectal CancerB A Conley, R S Kaplan, S G ArbuckSeminars in Oncology|August 1, 1993
Current dosage and schedule issues in the development of paclitaxel (Taxol)S G Arbuck, R Canetta, N Onetto, et al.Cancer Research|November 1, 1990
Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patientsC F Stewart, R A Fleming, S G Arbuck, et al.NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorinS G Arbuck, H O Douglass, F Trave, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trialJ A DeCaprio, R J Mayer, R Gonin, et al.Seminars in Oncology|December 1, 1992
Taxol: the first of the taxanes, an important new class of antitumor agentsE K Rowinsky, N Onetto, R M Canetta, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymesL Pendyala, S Madajewicz, S B Lele, et al.Pageof 7